TECHNE CORPORATION
HomeCompany NewsFinancial InformationAbout TechneMap - DirectionsProductsContact Us

Segment Results - 2nd Quarter Fiscal Year 2010

TECHNE CORPORATION AND SUBSIDIARIES
(in thousands of $’s, except per share data)

  Fiscal 2010 Increase (Decrease) From Fiscal 2009
  First Quarter Second Quarter YTD Percent Of Sales First Quarter Second Quarter YTD
Sales 66,534 65,521 132,055 100% (2,790) 3,645 855
Cost of sales 12,901 13,329 26,230 20% (185) (101) (286)
Gross margin 53,633 52,192 105,825 80% (2,605) 3,746 1,141
               
Gross margin percentage 80.6% 79.7% 80.1%        
               
SG&A expense 8,038 9,007 17,045 13% (802) (696) (1,498)
R&D expense 6,154 6,391 12,545 10% 244 545 789
Amortization expense 240 240 480 -- -- -- --
Interest income (1,168) (1,156) (2,324) (2%) 1,719 1,049 2,768
Other non-operating ex., net 662 1,011 1,673 1% (525) 299 (226)
  13,926 15,493 29,419 22% 636 1,197 1,833
Earnings before income taxes 39,707 36,699 76,406 58% (3,241) 2,549 (692)
Income taxes 12,935 11,978 24,913 19% (1,420) 1,467 47
26,772 24,721 51,493 39% (1,821) 1,082 (739)
Diluted earnings per share .72 .66 1.38        
Weighted average diluted shares outstanding 37,339 37,353 37,346        

Back to Top
HEMATOLOGY DIVISION
(in thousands of $’s)

  Fiscal 2010 Increase (Decrease) From Fiscal 2009
  First Quarter Second Quarter YTD Percent Of Sales First Quarter Second Quarter YTD
Sales 4,668 4,325 8,993 100% 422 65 487
Cost of sales 2,319 2,292 4,611 51% (50) (113) (163)
Gross margin 2,349 2,033 4,382 49% 472 178 650
               
Gross margin percentage 50.3% 47.0% 48.7%        
               
SG&A expense 370 366 736 8% (66) (32) (98)
R&D expense 198 201 399 4% 5 (2) 3
Interest, net (72) (72) (144) (1%) 30 19 49
  496 495 991 11% (31) (15) (46)
Pretax result 1,853 1,538 3,391 38% 503 193 696

Back to Top
BIOTECHNOLOGY DIVISION (1)
(in thousands of $’s)

  Fiscal 2010 Increase (Decrease) From Fiscal 2009
  First Quarter Second Quarter YTD Percent Of Sales First Quarter Second Quarter YTD
Sales 51,696 50,703 102,399 100% (2,203) 2,060 (143)
Intersegment sales (7,668) (8,282) (15,950) 94 29 123
  44,028 42,421 86,449   (2,109) 2,089 (20)
 
Cost of sales 9,885 10,126 20,011 20% (362) (964) (1,326)
Intersegment sales (7,598) (7,753) (15,351) (137) 586 449
  2,287 2,373 4,660   (499) (378) (877)
               
Gross margin 41,741 40,048 81,789 80% (1,610) 2,467 857
               
Gross margin percentage 80.9% 80.0% 80.5%        
               
SG&A expense 4,734 5,056 9,790 10% (407) (362) (769)
R&D expense 5,956 6,190 12,146 12% 239 547 786
Amortization expense 240 240 480 -- -- -- --
Interest, net (771) (772) (1,543) (1%) 313 198 511
Other expense 2 1 3 -- 4 -- 4
  10,161 10,715 20,876 21% 149 383 532
Pretax result 31,580 29,333 60,913 59% (1,759) 2,084 325

(1) Includes R&D Systems' Biotechnology Division, Fortron Bio Science, Inc., and BiosPacific, Inc.

Back to Top
R&D SYSTEMS EUROPE
(in thousands of £'s) 

  Fiscal 2010 Increase (Decrease) From Fiscal 2009
  First Quarter Second Quarter YTD Percent Of Sales First Quarter Second Quarter YTD
Sales 10,881 11,462 22,343 100% 706 265 971
Cost of sales 5,061 5,288 10,349 46% 801 (73) 728
Gross margin 5,820 6,174 11,994 54% (95) 338 243
               
Gross margin percentage 53.5% 53.9% 53.7%        
               
SG&A expense 1,191 1,318 2,509 11% (33) (46) (79)
Interest income (87) (79) (166) -- 703 504 1,207
Exchange loss/(gain) (89) 61 (28) -- (349) 96 (253)
  1,015 1,300 2,315 11% 321 554 875
Pretax result 4,805 4,874 9,679 43% (416) (216) (632)

Back to Top
R&D SYSTEMS EUROPE
(in thousands of $’s)

  Fiscal 2010 Increase (Decrease) From Fiscal 2009
  First Quarter Second Quarter YTD Percent Of Sales First Quarter Second Quarter YTD
Sales 17,838 18,775 36,613 100% (1,103) 1,491 388
Cost of sales 8,295 8,664 16,959 46% 364 390 754
Gross margin 9,543 10,111 19,654 54% (1,467) 1,101 (366)
               
Gross margin percentage 53.5% 53.9% 53.7%        
               
SG&A expense 1,952 2,159 4,111 11% (331) 65 (266)
Interest income (143) (128) (271) -- 1,328 778 2,106
Exchange loss (145) 99 46) -- (621) 94 (527)
  1,664 2,130 3,794 11% 376 937 1,313
Pretax result 7,879 7,981 15,860 43% (1,843) 164 (1,679)

Back to Top
CORPORATE AND OTHER (2)
(in thousands of $’s)

  Fiscal 2010 Increase (Decrease) From Fiscal 2009
  First Quarter Second Quarter YTD First Quarter Second Quarter YTD
Interest income 182 184 366 (48) (54) (102)
Rental income 81 115 196 (18) (16) (34)
  263 299 562 (66) (70) (136)
             
SG&A expense 982 1,426 2,408 2 (367) (365)
Other-Building expenses 548 530 1,078 (5) (21) (26)
Other-Equity Investment losses 338 496 834 79 210 289
  1,868 2,452 4,320 76 (178) (102)
Pretax result (1,605) (2,153) (3,758) (142) 108 (34)

Back to Top

(2) Unallocated corporate expenses and Techne’s share of losses by Hemerus Medical, LLC and Nephromics, LLC.



Home - Company News - Financial Information - About TECHNE - Map/Directions - Products - Contact Us

TECHNE CORPORATION
614 McKinley Place N.E.    Minneapolis, MN 55413-2610
Phone: (612)379-8854   Fax: (612)379-6580
e-mail: techinfo@techne-corp.com


* Up to a 15 minute delay on Market Overview. Please consult your financial advisor for an up-to-minute quote.
Quote provided by Barchart.com.